Analyst Price Target is $4.00
▲ +501.68% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 501.68% upside from the last price of $0.66.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Citius Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
Read More
